---
document_datetime: 2026-01-19 16:36:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/opuviz-epar-all-authorised-presentations_en.pdf
document_name: opuviz-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9293582
conversion_datetime: 2026-01-20 20:38:11.48097
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size                |
|------------------|-------------------|------------|------------------------|---------------------------|-----------------------|---------------------------|--------------------------|
| EU/1/24/1865/001 | Opuviz            | 40 mg/ml   | Solution for injection | Intravitreal use          | vial (glass)          | 0.1 ml                    | 1 vial                   |
| EU/1/24/1865/002 | Opuviz            | 40 mg/ml   | Solution for injection | Intravitreal use          | vial (glass)          | 0.1 ml                    | 1 vial + 1 filter needle |
| EU/1/24/1865/003 | Opuviz            | 40 mg/ml   | Solution for injection | Intravitreal use          | pre-filled syringe    | 0.1 ml                    | 1 pre-filled syringe     |